Xin Lang Zheng Quan·2025-11-24 03:13Core Viewpoint - Nuo Cheng Jian Hua's stock price has shown significant volatility, with a year-to-date increase of 94.22%, but a recent decline of 3.68% over the last five trading days, indicating potential market fluctuations and investor sentiment shifts [2]. Company Overview - Nuo Cheng Jian Hua, established on November 3, 2015, and listed on September 21, 2022, is a Chinese biopharmaceutical company focused on the research, production, and commercialization of drugs, particularly in oncology and autoimmune diseases [2]. - The company's product pipeline includes ICP-022, ICP-B04, ICP-490, ICP-192, and ICP-723, targeting unmet clinical needs [2]. - The revenue composition is primarily from drug sales (87.67%), followed by technology licensing (12.04%), and minimal contributions from testing and R&D services (0.15% each) [2]. Financial Performance - For the period from January to September 2025, Nuo Cheng Jian Hua reported a revenue of 1.115 billion yuan, reflecting a year-on-year growth of 59.85%, while the net profit attributable to shareholders was a loss of 64.415 million yuan, an improvement of 76.61% compared to the previous period [3]. - As of September 30, 2025, the number of shareholders increased by 8.66% to 16,500, indicating growing interest in the company [3]. Shareholder Composition - The top ten circulating shareholders include notable funds such as Fu Guo Precision Medical Flexible Allocation Mixed A and Wan Jia You Xuan, with some new entrants and changes in holdings among existing shareholders [3].